BRAF and non-small cell lung carcinoma: For example, EGFR inhibitors and BRAF inhibitors induce apoptosis by increasing the expression of BH3 only proapoptotic proteins such as BIM, PUMA and NOXA, and/or by decreasing expression of anti-apoptotic proteins such as BCL-2 and MCL-1 in cells derived from EGFR-mutant non-small cell lung cancers and BRAF-mutant melanomas, respectively [42–44].